Mercado mundial de la acromegalia: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado                              

La acromegalia es una enfermedad hormonal poco frecuente causada por la producción excesiva de hormona del crecimiento por parte de la glándula pituitaria entre la pubertad y la madurez. La hormona del crecimiento , que es producida por la glándula pituitaria y liberada en el torrente sanguíneo, hace que el hígado produzca una hormona llamada factor de crecimiento similar a la insulina tipo I (IGF-I), que estimula el crecimiento de los huesos y los tejidos. Los niveles excesivos de IGF-I impulsados ​​por la sobreproducción de la hormona del crecimiento pueden provocar una expansión de los tejidos blandos y del esqueleto. La acromegalia es más común en personas de mediana edad, sin embargo, puede afectar o desarrollarse a cualquier edad. La acromegalia es un trastorno que puede tardar mucho tiempo en reconocerse y, como resultado, puede causar problemas importantes e incluso la muerte.

Data Bridge Market Research analiza que el mercado de la acromegalia se valoró en USD 1.51 mil millones en 2021 y se espera que alcance los USD 5.81 mil millones para 2029, registrando una CAGR del 8,00% durante el período de pronóstico de 2022 a 2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis de expertos en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado

Definición de mercado

La acromegalia es una afección en la que hay demasiada hormona del crecimiento (GH) en el cuerpo. La GH anormal generalmente se corrige mediante cirugía para extirpar el tumor hipofisario que está causando esta enfermedad. La acromegalia no siempre se cura porque el tumor es demasiado grande para extirparlo por completo. Se pueden usar medicamentos y radiación ( radioterapia ) para tratar la acromegalia en esta situación. Se usan medicamentos para tratar a algunas personas que tienen tumores que son demasiado difíciles de extirpar quirúrgicamente. Estos medicamentos pueden detener la producción de GH por parte de la glándula pituitaria o impedir que actúe en otras partes del cuerpo. Después del tratamiento, deberá visitar a su médico todos los meses para asegurarse de que la glándula pituitaria esté funcionando correctamente y de que la acromegalia no haya regresado. Las evaluaciones deben realizarse al menos una vez al año.

Dinámica del mercado de la acromegalia

Conductores

• Aumento de la incidencia de la acromegalia

La creciente incidencia de la acromegalia actuará como un factor importante que dará lugar a la expansión de la tasa de crecimiento del mercado. La acromegalia y los tumores hipofisarios son cada vez más comunes, lo que está impulsando la expansión del mercado. Según un estudio de mayo de 2021 titulado "Epidemiología descriptiva y análisis de supervivencia de la acromegalia en Corea", la incidencia anual media fue de 4,2 casos por millón al año durante este período de tiempo, y la prevalencia fue de 32,1 casos por millón. La acromegalia es una enfermedad fascinante que se diagnostica con mayor frecuencia en adultos de mediana edad y afecta a entre 5 y 8 personas de cada 100.000 personas.

• Aumentar la inversión en infraestructura sanitaria

Another significant factor influencing the growth rate of acromegaly market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, surging number of government initiatives to spread awareness and rising prevalence of genetic diseases will result in the expansion of acromegaly market. Along with this, rising level of disposable income and changing lifestyle of people will enhance the growth rate of the market. The increasing incidence of hormonal diseases, such as hypopituitarism and endocrine diseases is estimated to enhance the market's growth rate.

Opportunities

• Rise in R & D activities  

The market's growth is fueled by growing number of research and development activities. This will provide beneficial opportunities for the acromegaly market growth. Seven somatostatin analogues and two growth hormone receptor antagonists, for instance, are scheduled to be approved by the FDA by 2027. Furthermore, the introduction of technologically enhanced detection techniques such as radiosurgery and radio labelled imaging technologies that are cost effective and have little side effects is estimated to provide a growth platform for this industry.

Moreover, the market's growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the acromegaly market growth.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the growth rate of acromegaly market during the forecast period of 2022-2029. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the acromegaly market. Additionally, lack of awareness among people and poor reimbursement policies will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This acromegaly market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acromegaly market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Acromegaly market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period. 

COVID-19 Impact on Acromegaly Market

In the last year and a half, the majority of companies around the world have been adversely affected. This may be attributed to essential interruptions in their assembling and production network activities as a result of various preliminary lockdowns as well as various constraints imposed by overseeing specialists throughout the world. A similar situation exists in the global acromegaly market. Additionally, shopper demand has reduced along these lines, as people are now quicker to eliminate superfluous charges from their budgets, as this flare-up has severely hit most people's total financial situation.

These above-mentioned factors are expected to wreak havoc on the global acromegaly market's revenue trajectory over the forecast period. However, when individual administering professionals reduce these imposed restraints, the global acromegaly market is expected to recover as demand grows.

Recent Development

• In August 2020, Chiasma, Inc. announced the commercial launch and availability of MYCAPSSA (octreotide) capsules in the United States for patients with acromegaly. MYCAPSSA (octreotide) delayed-release capsules for oral administration are a somatostatin analog intended for long-term maintenance therapy in acromegaly patients who have responded to and tolerated octreotide or lanreotide treatment.

Global Acromegaly Market Scope

The acromegaly market is segmented on the basis of type, diagnosis, complications, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Complications

• Local
• Systemic
• CNS
• CVS
• Respiratory
• Endocrine and metabolic
• Neoplastic
• Skeletal
• Others
• Others

Type

• Ectopic Acromegaly
• Acromegaly Due to Growth Hormone

Diagnosis

• GH and IGF-I Measurement
• Growth Hormone Suppression Test
• Imaging
• Spine x-ray
• MRI of the brain, including the pituitary gland
• Echocardiogram
• Colonoscopy
• Others

Treatment

• Medication
• Somatostatin analogues
• Dopamine agonists
• Growth hormone antagonist
• Others
• Surgery
• Radiation
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Acromegaly Market Regional Analysis/Insights

The acromegaly market is analysed and market size insights and trends are provided by country, type, diagnosis, complications, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the acromegaly market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the acromegaly market because of the rising healthcare expenditure and increased high prevalence of pituitary tumor in this region. Additionally, the growing focus of major key players in research and development activities will further propel the market's growth rate.

Asia-Pacific is expected to grow significantly during the forecast period of 2022-2029 due to increased hormone related disorders and surgeries in this region. Also, development of healthcare infrastructure and large number of generic manufacturer will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Acromegaly Market Share Analysis

The acromegaly market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to acromegaly market.

Some of the major players operating in the acromegaly market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (Estados Unidos)
• Hikma Pharmaceuticals PLC (Reino Unido)
• Compañía Bristol-Myers Squibb (Estados Unidos)
• Bayer AG (Alemania)
• Boehringer Ingelheim International GmbH (Alemania)
• Laboratorios Dr. Reddy Ltd. (India)
• Gilead Sciences, Inc. (Estados Unidos)
• Amgen Inc. (Estados Unidos)
• Eli Lilly and Company (Estados Unidos)
• AbbVie Inc. (Estados Unidos)
• Lupino (India)
• Allergan (Irlanda)

SKU-53448